T. Rowe Price Investment Management
AGIO icon

T. Rowe Price Investment Management’s Agios Pharmaceuticals AGIO Stock Holding History

T. Rowe Price Investment Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$50.4M Buy
1,488,740
+1,487,848
+166,799% +$42.2M 0.03% 356
2025
Q4 		$25K Buy
+892
New +$31.3K ﹤0.01% 681
2024
Q2 		– Sell
-928,596
Closed -$27.2M – 622
2024
Q1 		$27.2M Sell
928,596
-1,310
-0.1% -$35.1K 0.02% 475
2023
Q4 		$20.7M Sell
929,906
-145
-0% -$3.25K 0.01% 479
2023
Q3 		$23M Hold
930,051
– – 0.02% 462
2023
Q2 		$26.3M Sell
930,051
-37,200
-4% -$926K 0.02% 456
2023
Q1 		$22.2M Sell
967,251
-11,862
-1% -$315K 0.02% 462
2022
Q4 		$27.5M Sell
979,113
-10,346
-1% -$292K 0.02% 424
2022
Q3 		$28M Buy
+989,459
New +$26.5M 0.02% 419

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

T. Rowe Price Investment Management's AGIO Position: Q1 2026 in Review

T. Rowe Price Investment Management increased its Agios Pharmaceuticals (AGIO) stake by 166,799% in Q1 2026, buying an estimated $42.2M and bringing the position to 1,488,740 shares worth $50.4M. The position accounts for 0.03% of the portfolio, ranked #356.

T. Rowe Price Investment Management first reported a position in AGIO in Q3 2022 and has held it in 9 quarters since. 233 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • T. Rowe Price Investment Management held 1,488,740 shares of Agios Pharmaceuticals worth $50.4M as of Q1 2026.
  • T. Rowe Price Investment Management bought 1,487,848 Agios Pharmaceuticals shares in Q1 2026, an estimated $42.2M.
  • Agios Pharmaceuticals made up 0.03% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #356 holding.
  • T. Rowe Price Investment Management first reported a position in Agios Pharmaceuticals in Q3 2022 and has held it in 9 quarters since.
  • 233 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.